Switzer TV | Stocks slide, is now the time to buy anyway? Red flags for SpaceX IPO
Daniel Tillett, Racura Oncology: the Australian biotech that says it has cracked a cancer target left untouched for 40 years, and why its shareholders keep backing it.
Watch below:
0
likes
•
0
questions
•
0
company answers
Ask a question
Your question will be sent privately to Racura Oncology. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Racura Oncology a question about this update.